Avanos Medical Q3 sales beat estimates

Avanos Medical

05/11/2025 12:24

Overview

Avanos Q3 2025 sales rose 4.3%, beating analyst expectations

Company reported a Q3 net loss of $1.4 mln, down from $5.9 mln net income last year

Company raises full-year revenue and adjusted EPS guidance

Outlook

Avanos raises 2025 revenue guidance to $690 mln - $700 mln

Avanos increases 2025 adjusted EPS guidance to $0.85 - $0.95

Company cites tariff uncertainty affecting financial outlook

Result Drivers

SPECIALTY NUTRITION GROWTH - Double-digit growth in SNS segment driven by demand in enteral feeding and neonate solutions

NEXUS MEDICAL ACQUISITION - Acquisition adds complementary technology to SNS segment, expected to benefit NICU and PICU care

PAIN MANAGEMENT MIXED RESULTS - RFA product sales grew, offset by decline in surgical pain and recovery products

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$177.80 mln
$164.50 mln (1 Analyst)
Q3 Net Income
-$1.40 mln
Q3 EBITDA
$9.50 mln
Q3 Gross Profit
$86 mln
Q3 Operating Income
$100,000
Q3 Pretax Profit
-$1.20 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nPn5D6ThKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)